Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)
PHASE3CompletedINTERVENTIONAL
Enrollment
481
Participants
Timeline
Start Date
April 21, 2005
Primary Completion Date
June 15, 2007
Study Completion Date
August 2, 2007
Conditions
Schizophrenia
Interventions
DRUG
asenapine
5-10 mg sublingually twice daily for 26 weeks
DRUG
olanzapine
5-20 mg by mouth once daily for 26 weeks
All Listed Sponsors
lead
Organon and Co
INDUSTRY
NCT00212836 - Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817) | Biotech Hunter | Biotech Hunter